Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to get started, it's crucial to pick stocks that have the tools to perform well for decades to come. Corporations that fit this criteria are a rare breed, but they do exist.Below, I'll look at two companies in the healthcare sector: Eli Lilly (LLY 2.45%) and Vertex Pharmaceuticals (VRTX -0.03%). For those with $5,000 to invest that's not being saved for routine expenses or emergencies, pur ...

Market Overview - Berkshire Hathaway is valued at $1 trillion, making it a significant player in the market, though it is smaller than Apple ($3.5 trillion), Nvidia ($3.4 trillion), and Microsoft ($3.2 trillion) [1][2] - Despite its size, Berkshire Hathaway is not expected to lose value and is likely to grow its market capitalization over the next five years [3] Berkshire Hathaway's Challenges - Berkshire Hathaway faces a lack of investment opportunities that interest Warren Buffett and his team, leading to a cash-heavy balance sheet [4] - The company's privately held businesses, such as Geico, Shaw, Duracell, and Fruit of the Loom, make up a significant portion of its current capitalization [4] Growth Prospects Beyond Berkshire Hathaway Eli Lilly - Eli Lilly's revenue is heavily driven by its diabetes treatment Mounjaro (27% of revenue) and weight-loss drug Zepbound (11% of revenue) [6] - GlobalData predicts Mounjaro's annual sales could reach $27 billion to $34 billion by 2029, up from its current annualized revenue of $12 billion [8] - The anti-obesity drug market, overlapping with diabetes treatment, is projected to be worth $100 billion annually by 2030, offering significant growth potential [9] - Eli Lilly's current market cap is approximately $650 billion, positioning it as a potential candidate to surpass Berkshire Hathaway in size [10] Visa - Visa consistently outpaces global spending growth due to the shift from cash and checks to card-based payments [12] - In the US, cash usage dropped from 31% of transactions in 2016 to 16% in 2023, while credit card usage rose from 18% to 32% [13] - E-commerce growth further drives card-based transactions, with only 16% of domestic retail spending currently done online, leaving room for expansion [14] - Visa's innovation efforts, including its global Innovation Centers, contribute to its annual revenue growth of 8% to 15% and strong profit growth [15][16] - Berkshire Hathaway holds an 8.3 million share/$2.6 billion stake in Visa, highlighting its investment appeal [17] Taiwan Semiconductor Manufacturing Company (TSMC) - TSMC is a leading third-party semiconductor manufacturer, serving major clients like Apple, Nvidia, and Qualcomm [21] - The global semiconductor market is expected to grow more than twice as fast as global GDP, reaching over $1 trillion annually by 2030 [22] - TSMC's market cap is already around $1 trillion, making it a strong candidate to surpass Berkshire Hathaway in size [19] - The company benefits from the rapid growth of AI and data centers, which drive demand for advanced semiconductors [22]

Core Viewpoint - The Thurgood Marshall College Fund (TMCF) has received a $25 million grant from Lilly Endowment Inc. to enhance capacity at TMCF and its member historically Black colleges and universities (HBCUs) [2][3][4] Group 1: Grant Purpose and Impact - The grant will fund Project HBCU Capacity Building, aimed at maximizing HBCU performance through investments in research, operations, and innovation [2] - TMCF will address infrastructure needs and accelerate innovation across HBCUs, enhancing student support and empowering campuses to pursue underfunded initiatives [2][4] - The initiative is expected to lead to substantial improvements in institutional capacity outcomes across participating HBCUs over five years [7] Group 2: Strategies for Implementation - TMCF will enhance administrative systems and processes by implementing a data management system and developing tailored professional development offerings for staff [4] - Collaborative learning cohorts will be facilitated among TMCF member institutions to share best practices and resources in areas such as enrollment and student support services [5] - Grant opportunities and technical assistance will be provided to select TMCF member institutions to strengthen faculty research, improve student retention, and upgrade technology systems [6] Group 3: Organizational Background - TMCF, established in 1987, is the largest organization representing the Black college community, supporting nearly 80% of students attending Black colleges and universities [8] - Lilly Endowment Inc., founded in 1937, supports community development, education, and religion, with a special commitment to its hometown of Indianapolis and home state of Indiana [9]

Pharmaceutical and Biotech Industry Overview - The pharmaceutical and biotech industry generally offers steady revenue performance due to the essential nature of medicines, but certain companies exhibit growth-like behavior when they innovate rapidly or operate in high-growth areas [1] Eli Lilly - Eli Lilly has experienced significant growth driven by its weight-loss drugs, Zepbound and Mounjaro, which generated $1.2 billion and $3.1 billion in revenue respectively in the most recent quarter [3] - The company is increasing production of these drugs, expecting a 60% rise in doses in the first half of this year compared to the same period last year [4] - Analysts predict the obesity drug market could reach $100 billion to $130 billion by 2030, positioning Eli Lilly for potential long-term stock price gains despite a 200% increase over the past three years [5] Vertex Pharmaceuticals - Vertex Pharmaceuticals is a global leader in cystic fibrosis treatment, with product revenue exceeding $2.7 billion in the recent quarter, driven by its top-selling drug Trikafta [6][7] - The company recently gained FDA approval for Alyftrek, a more efficacious and convenient once-daily cystic fibrosis treatment [6] - Vertex has applied for FDA approval of suzetrigine, a non-opioid candidate for moderate-to-severe acute pain, with a decision expected by the end of January, potentially representing a significant near-term catalyst [8] - If approved, suzetrigine could become a multibillion-dollar drug, offering a major long-term growth opportunity in the pain management market [9] - Vertex's stock has climbed 87% over the past three years, with further growth potential due to its innovative pipeline [10]

Financial Results Announcement - Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6, 2025 [1] - A conference call will be held on the same day to discuss the company's financial performance and guidance [1] Conference Call Details - The conference call will begin at 10 a.m. Eastern time [2] - Investors, media, and the general public can access a live webcast through a link on Lilly's website, with a replay available afterward [2] Company Overview - Eli Lilly is a medicine company focused on turning science into healing, with nearly 150 years of pioneering life-changing discoveries [3] - The company aims to address significant health challenges, including diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [3] - Lilly is committed to delivering innovative clinical trials that reflect global diversity and ensuring the accessibility and affordability of its medicines [3]

Stock Performance - Eli Lilly closed at $753 98, marking a +1 57% move from the previous day, outpacing the S&P 500's daily gain of 0 61% [1] - Shares of the company had lost 6 7% over the past month, lagging the Medical sector's gain of 1 64% and the S&P 500's gain of 2 08% [1] Earnings and Revenue Projections - The company is predicted to post an EPS of $5 22, indicating a 109 64% growth compared to the equivalent quarter last year [2] - Revenue is expected to be $13 49 billion, showing a 44 23% escalation compared to the year-ago quarter [2] Analyst Estimates and Zacks Rank - Recent adjustments to analyst estimates reflect the latest near-term business trends, with upbeat changes indicating a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has an impressive track record, with 1 stocks generating an average annual return of +25% since 1988 [4][5] - Eli Lilly currently possesses a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Eli Lilly has a Forward P/E ratio of 31 3, indicating a premium compared to its industry's Forward P/E of 12 61 [6] - The company has a PEG ratio of 1 56, compared to the industry average of 1 32 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and currently holds a Zacks Industry Rank of 207, positioning it in the bottom 18% of all 250+ industries [7] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Eli Lilly and Company shares are experiencing a rebound after a decline due to preliminary sales figures of $45 billion, which fell short of the expected $46 billion, indicating potential for recovery in stock price [1]. Group 1: Stock Performance - Following a drop in stock price, there is optimism that the decline may have reached its bottom, with expectations for a rebound [1]. - The stock has found support around the $722 level, which has historically acted as a price floor [2][6]. Group 2: Market Dynamics - A downtrend occurs when there is more supply than demand, leading to discounted selling prices [3]. - At support levels, demand increases sufficiently to absorb supply, stabilizing the stock price [3]. - Regretful sellers from previous highs often return to buy at the same price, reinforcing support levels [4][5]. Group 3: Historical Context - The $722 support level has been tested multiple times, with previous rebounds following similar price action [5][6]. - The presence of buy orders from investors who sold at this level in the past contributes to the formation of support [4][5].

Group 1 - Eli Lilly updated its revenue guidance for Q4 FY24, reducing the forecast by $400 million, leading to an over 8% drop in stock price despite only a 0.6% reduction in revenue projections [1] Group 2 - The company employs a research-driven approach to identify high-conviction stocks with growth potential in sectors such as big tech, semiconductors, AI, and healthcare [2] - The analysis includes both low-risk and selective high-risk investment opportunities that may outperform the market [2] - Each investment idea is supported by thorough research and strategic foresight to help investors navigate complex markets [2]

Core Insights - Medicare has introduced price controls on 15 prescription medications, including Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic, aimed at reducing financial burdens for seniors [1][2] Group 1: Drug Price Control Implementation - The price controls for the selected drugs will take effect in 2027 [2] - The Inflation Reduction Act (IRA) allows Medicare to set lower prices on high-expenditure drugs, with the Centers for Medicare & Medicaid Services (CMS) empowered to establish a "maximum fair price" [3][4] - Pharmaceutical companies must agree to the set prices, or face a daily excise tax on sales exceeding the maximum fair price [4] Group 2: Industry Response and Concerns - Novo Nordisk has expressed opposition to government price setting, citing concerns about access to medicines and potential negative impacts on future drug development [4] - A coalition of over 40 groups has called for the repeal of the Drug Price Negotiation Program, arguing it may lead to medicine shortages and increased costs [4][5] Group 3: Impact on Medicare and Drug Usage - Approximately 5.3 million Medicare Part D recipients utilized the newly selected drugs, which accounted for about $41 billion, or 14%, of total Medicare Part D prescription costs from November 2023 to October 2024 [6]

Eli Lilly's Market Performance - Eli Lilly became the world's largest healthcare company with a market cap exceeding $860 billion during its nearly four-year run starting in late 2020 [1] - The company's stock has significantly pulled back over the last eight weeks, including a recent sell-off after cutting its 2024 revenue guidance due to lower-than-expected demand for its obesity and diabetes drugs [2] Trump's Tariff Policies - Trump proposed tariffs of at least 10% and up to 20% on all imports, with higher rates for specific countries like Canada (25%), Mexico (25%), and China (60%) [3][4][5] - The president-elect plans to create an "External Revenue Service" to collect tariffs, a responsibility currently handled by U S Customs and Border Protection [4] - Tariffs typically lead to higher prices for imported products, with costs usually passed on to consumers [6] Impact on Novo Nordisk and Eli Lilly - Novo Nordisk, based in Denmark, faces potential high tariffs under Trump's policies, which could increase prices for its drugs Ozempic and Wegovy [7][8] - Novo Nordisk's management expressed concern but did not comment on potential price impacts, stating they remain focused on delivering medicines [9] - Higher prices for Ozempic and Wegovy could benefit Eli Lilly by increasing demand for its competing drugs Mounjaro and Zepbound, especially if insurers favor Lilly's products to reduce costs [10] Future Outlook for Eli Lilly - Eli Lilly's sales for Mounjaro and Zepbound are expected to continue growing, with potential new product launches like the obesity drug orforglipron in early 2026 and the Alzheimer's drug Kisunla gaining momentum [13] - While Trump's tariffs may or may not make Eli Lilly a no-brainer stock in 2025, the company remains a strong investment regardless of political developments [13]